65 results
8-K
EX-99.1
ANNX
Annexon Inc
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
, multi-center Phase 3 clinical trial (N=241) designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ANX005 in patients
8-K
EX-99.1
ANNX
Annexon Inc
7 May 24
Other Events
4:05pm
safety profile with no incidence of vasculitis hold promise to impact loss of visual acuity within the current treatment landscape.”
Key Additional
424B5
ANNX
Annexon Inc
5 Apr 24
Prospectus supplement for primary offering
4:07pm
volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, ANX1502 was generally well tolerated
8-K
EX-99.1
a9r51b ju7p5pltydpoc
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
228q7q g9njb
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
ndgclt
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-1.1
9aw5d
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
fgf40f ht
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
azca00 rjebkpz
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.4
la7zwfysxjefv3
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
hcf93pvs5 uh
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.2
sl8kq2
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
vp9un7ak xn
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
EX-99.2
cpl7c5vc71wxz61c9t
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm